about
Synthesis, SAR, and X-ray structure of tricyclic compounds as potent FBPase inhibitorsDesign and discovery of new (3S,5R)-5-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]piperidine-3-carboxamides as potent renin inhibitorsDiscovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist.Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor.Asymmetric synthesis of 2-substituted-3-aminocarbonyl propionic acid.Discovery of potent and orally active tricyclic-based FBPase inhibitors.Lead optimization of 5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxyhexanamides to reduce a cardiac safety issue: discovery of DS-8108b, an orally active renin inhibitor.Synthesis and optimization of novel (3S,5R)-5-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)piperidine-3-carboxamides as orally active renin inhibitors.Synthesis and evaluation of CS-2100, a potent, orally active and S1P(3)- sparing S1P(1) agonist.Synthesis and evaluation of thiomannosides, potent and orally active FimH inhibitorsStudies of HIV-1 protease inhibitors. II. Incorporation of four types of hydroxyethylene dipeptide isosteres at the scissile site of substrate sequencesDiastereoselective Dieckmann condensation suitable for introduction of the duocarmycin A C6 center: development of a divergent strategy for the total synthesis of duocarmycins A and SAStereospecific synthesis of a 1 beta-methylcarbapenem intermediateSynthesis of 2-phenylbenzofuran derivatives as testosterone 5 alpha-reductase inhibitorSynthesis and 5 alpha-reductase inhibitory activities of benzofuran derivatives with a carbamoyl groupSynthesis and SAR of 1,3-thiazolyl thiophene and pyridine derivatives as potent, orally active and S1P₃-sparing S1P₁ agonistsSynthesis and SAR studies of benzyl ether derivatives as potent orally active S1P₁ agonistsPractical one-step glucuronidation via biotransformation
P50
Q27657466-EB957E69-C7CB-465F-82D5-4ECE5527E9C1Q27683188-DE3F1E05-0885-4570-B4C6-ADED7E0D2651Q34248614-13C0BBFD-861B-44BB-AEB8-78356BA96FE5Q39507555-3DAF8E17-198C-457D-98CD-3D94F2CC298BQ39731135-74040D76-EC05-439C-BF6A-5019803B3363Q41946139-7A2E67B6-6EF0-48F2-8D89-990D38031D5AQ43027753-2614FF61-E37F-4D97-B9A4-409FE4E72013Q43813792-E573B20B-DB63-4942-9AD0-588D8A7DE1AEQ45041164-7989715B-E3EF-4EB7-84F6-44F630B6E434Q53646728-B2460F81-6582-46DF-ABCC-4A8777E18697Q64448549-1F4052E2-EB38-4425-92A8-32BFBBAD158BQ70488714-F318A594-3C8C-404E-90CD-93B4EF6F0940Q71031042-6CA5FD33-37DA-4538-84CF-FA23C0896D49Q73477621-778780F9-AB13-4D4A-8705-C234F03B4D4EQ74594582-9AE95269-D551-4A35-8276-58942B752231Q77743946-33E05294-70D8-49DD-AAA5-E6A6602C153DQ83839435-0DC83ADE-A968-41A2-A42E-A3B4925A2F53Q88040054-99F0F19F-EAC6-42D4-BCC7-DF40F6A43175Q90519448-E3137829-0504-4D24-953E-483C7E0337B4
P50
description
researcher
@en
name
T Nishi
@ast
T Nishi
@en
T Nishi
@nl
type
label
T Nishi
@ast
T Nishi
@en
T Nishi
@nl
prefLabel
T Nishi
@ast
T Nishi
@en
T Nishi
@nl
P106
P31
P496
0000-0002-6222-9711